Squarepoint
SPRO icon

Squarepoint’s Spero Therapeutics SPRO Stock Holding History

Squarepoint’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$455K Buy
194,301
+74,867
+63% +$178K ﹤0.01% 3389
2025
Q4 		$278K Buy
+119,434
New +$277K ﹤0.01% 3661
2025
Q2 		– Sell
-92,939
Closed -$66.9K – 5018
2025
Q1 		$66.9K Buy
92,939
+37,888
+69% +$32K ﹤0.01% 4305
2024
Q4 		$56.7K Buy
+55,051
New +$65.5K ﹤0.01% 4817
2024
Q2 		– Sell
-79,401
Closed -$137K – 4615
2024
Q1 		$137K Sell
79,401
-43,401
-35% -$68K ﹤0.01% 3728
2023
Q4 		$181K Sell
122,802
-6,695
-5% -$7.98K ﹤0.01% 3635
2023
Q3 		$157K Buy
129,497
+51,434
+66% +$71.3K ﹤0.01% 3479
2023
Q2 		$113K Buy
+78,063
New +$134K ﹤0.01% 3343
2022
Q4 		– Sell
-16,423
Closed -$33K – 3577
2022
Q3 		$33K Buy
+16,423
New +$16.3K ﹤0.01% 2889
2020
Q4 		– Sell
-14,690
Closed -$164K – 3237
2020
Q3 		$164K Sell
14,690
-14,718
-50% -$174K ﹤0.01% 2165
2020
Q2 		$398K Buy
29,408
+9,019
+44% +$101K 0.01% 1430
2020
Q1 		$165K Buy
20,389
+2,386
+13% +$21K ﹤0.01% 1539
2019
Q4 		$173K Buy
+18,003
New +$194K ﹤0.01% 2253
2019
Q2 		– Sell
-12,951
Closed -$166K – 2651
2019
Q1 		$166K Buy
+12,951
New +$137K ﹤0.01% 1975

Other funds holding SPRO

GP
GSK plc London $599M AUM
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Squarepoint's SPRO Position: Q1 2026 in Review

Squarepoint increased its Spero Therapeutics (SPRO) stake by 63% in Q1 2026, buying an estimated $178K and bringing the position to 194,301 shares worth $455K. The position accounts for ﹤0.01% of the portfolio, ranked #3389.

Squarepoint first reported a position in SPRO in Q1 2019 and has held it in 14 quarters since. 50 funds tracked by Wall St. Rank hold SPRO as of Q1 2026.

  • Squarepoint held 194,301 shares of Spero Therapeutics worth $455K as of Q1 2026.
  • Squarepoint bought 74,867 Spero Therapeutics shares in Q1 2026, an estimated $178K.
  • Spero Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #3389 holding.
  • Squarepoint first reported a position in Spero Therapeutics in Q1 2019 and has held it in 14 quarters since.
  • 50 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.